Cargando…
Severity of COVID-19 in patients with lung cancer: evidence and challenges
Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age and comorbidities. Patients with lung cancer have...
Autores principales: | Passaro, Antonio, Bestvina, Christine, Velez Velez, Maria, Garassino, Marina Chiara, Garon, Edward, Peters, Solange |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978268/ https://www.ncbi.nlm.nih.gov/pubmed/33737345 http://dx.doi.org/10.1136/jitc-2020-002266 |
Ejemplares similares
-
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
por: Hines, Jacobi B., et al.
Publicado: (2023) -
AB012. Automated histologic subtyping of thymic epithelial tumors with deep learning
por: Dolezal, James M., et al.
Publicado: (2022) -
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
por: Cameron, Robert B., et al.
Publicado: (2023) -
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020) -
Challenges in lung cancer therapy during the COVID-19 pandemic
por: Calabrò, Luana, et al.
Publicado: (2020)